The Technical Analyst
Odyssey Group [ODYY]
Exchange: PNK Industry: Medical Devices
Odyssey Group Price, Forecast, Insider, Ratings, Fundamentals & Signals
-12.33% $0.0320
America/New_York / 3 mai 2024 @ 15:58
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 3.08 mill |
| EPS: | 0.100 |
| P/E: | 0.320 |
| Earnings Date: | Apr 29, 2023 |
| SharesOutstanding: | 96.36 mill |
| Avg Daily Volume: | 0.0937 mill |
| RATING 2024-05-03 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | ||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0.320 | sector: PE -11.58 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE 0.320 | industry: PE -6.92 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.0255 (-179.67%) $-0.0575 |
| Date: 2024-05-04 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.0170 - 0.0470 ( +/- 46.88%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-01-16 | Gironda Gregory W | Buy | 37 500 | Stock Option (Right to Buy) |
| 2024-01-16 | Emerson Erik C. | Buy | 37 500 | Stock Option (Right to Buy) |
| 2024-01-10 | Gandolfo John P | Buy | 1 500 000 | ODYY - Common Stock |
| 2024-01-10 | Gandolfo John P | Sell | 1 500 000 | Restricted Stock Unit (Right to Buy) |
| 2023-12-29 | Emerson Erik C. | Buy | 200 000 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 56.71 |
| Last 49 transactions |
| Buy: 18 200 000 | Sell: 33 775 000 |
Forecast:
16:00 - $0.0320
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $0.0320 (-12.33% ) |
| Volume | 0.0315 mill |
| Avg. Vol. | 0.0937 mill |
| % of Avg. Vol | 33.63 % |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ODYY
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
ODYY
Odyssey Health, Inc., a medical company, focuses on developing medical products. It develops CardioMap, a heart monitoring and screening device; Save A Life choking rescue devices; and PRV-001 and PRV-002 neurosteroid drug compounds to treat concussions and rare brain disorders. The company was formerly known as Odyssey Group International, Inc. Odyssey Health, Inc. was founded in 2014 and is based in Las Vegas, Nevada.
Latest Press Releases
2024-03-27 08:30:00 - Press Release
Odyssey Health, Inc. Strengthens Balance Sheet With $8.7 Million In Net Equity
Las vegas, nv / accesswire / march 27, 2024 / odyssey health, inc. (otcqb:odyy), formerly odyssey group international, inc., (the "company") a company focused on developing unique, life-enhancing medical products, recently filed its quarterly report for the quarter ended january 31, 2024. the company reported $13.2 million in net income attributable to stockholders and total stockholder equity of $8.7 million.
2024-01-02 08:30:00 - Press Release
Odyssey Health Closes Asset Sale Of Its Neurological Drug Technology Pipeline Including Concussion Drug Candidate With Oragenics, Inc.
Las vegas, nv / accesswire / january 2, 2024 / odyssey health, inc. (otcqb:odyy) ("odyssey" or the "company") today announces the closing of the definitive asset purchase agreement, that was entered into on october 4, 2023, with oragenics, inc., (ogen:nyse american) under which oragenics acquired odyssey's proprietary assets related to its neurological drug therapy platform under dvelopment. the assets include drug candidates for treating mild traumatic brain injury (mtbi), also known as concussion, and for treating niemann pick disease type c (npc), as well as odyssey's proprietary powder formulation and its nasal delivery device.
2023-12-12 08:30:00 - Press Release
Odyssey Health, Inc. Gains Shareholder Approval For Asset Sale With Oragenics, Inc.
Las vegas, nv / accesswire / december 12, 2023 / odyssey health, inc. (otcob:odyy), a company focused on developing unique, life-enhancing medical products including a drug treatment intended to treat concussion, announces that it has received stockholder approval for the sale of its neurological drug platform technology. a special meeting of odyssey stockholders was held on december 7, 2023, at the law offices of brinen &associates.
2023-11-16 08:30:00 - Press Release
Odyssey Health, Inc, Selects Syneos Health To Support Investigational New Drug Application For Treatment Of Concussion
Las vegas, nv / accesswire / november 16, 2023 / odyssey health, inc. (otcqb:odyy), f/k/a odyssey group international, inc., a company focused on developing unique, life-enhancing medical products, has selected syneos health®, a leading fully integrated biopharmaceutical solutions organization to support its investigational new drug (ind) application. odyssey health is developing a pharmaceutical treatment for mild traumatic brain injury (mtbi), aka concussion.
2023-11-15 12:00:00 - Press Release
Odyssey Health, Inc. To Provide Company Update And Webcast For Shareholders
Las vegas, nv / accesswire / november 15, 2023 / odyssey health, inc. (otcqb:odyy), formerly odyssey group international, inc., a company focused on developing unique, life-enhancing medical products, will hold a webcast to provide an update on the company and recap its progress. the webcast will be held on november 16, 2023, at 4:00 pm est.
Latest News
2023-11-15 12:00:00 - Accesswire
Odyssey Health, Inc. to Provide Company Update and Webcast for Shareholders
LAS VEGAS, NV / ACCESSWIRE / November 15, 2023 / Odyssey Health, Inc. (OTCQB:ODYY), formerly Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, will hold a webcast to provide an update on the Company and recap its progress. The Webcast will be held on November 16, 2023, at 4:00 PM EST.
2021-10-19 10:03:00 - GlobeNewsWire
Odyssey Group International Files Patent On Novel Breath-Propelled Nasal Delivery Device
IRVINE, CA, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTC:ODYY) (the "Company" or "Odyssey"), a medical technology company focused on developing unique, life-saving medical products, today announced the filing of a provisional patent on its novel nasal drug delivery device. The device and drug combination will be used in Odyssey's sponsored current clinical trial for treating concussion.
2021-09-22 08:39:00 - GlobeNewsWire
Odyssey Group International Begins Enrolling Subjects for Phase 1 Clinical Trial to Treat Concussion
IRVINE, CA, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTC: ODYY ) (the "Company" or "Odyssey"), a medical company focused on developing unique, life-saving medical products, today announced successful completion of their clinical trial site initiation visit and the start of subject screening and enrollment. The drug candidate PRV-002 is being developed to treat concussion as a novel neurosteroid delivered nasally. Odyssey's Phase 1 clinical trial status can be viewed at www.clinicaltrials.gov.
2021-09-01 08:30:00 - GlobeNewsWire
Odyssey Group International Approved to Start Human Trial to Treat Concussion
IRVINE, CA, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTC: ODYY ) (the "Company" or "Odyssey"), a company focused on developing unique, life-saving medical products, today announced its approval to begin Phase 1 human clinical trials for drug candidate PRV-002 intended to treat concussions. The Company's Clinical Trial Protocol was approved by the Alfred Ethics Committee and allows for the immediate start of the human trial.
2021-08-04 09:25:00 - GlobeNewsWire
Odyssey Group International Completes IND-enabling Studies, Submits Investigator's Brochure for Phase 1 Clinical Trial
IRVINE, CA, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTC: ODYY ) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, today announced the successful completion of their Investigational New Drug (“IND”) enabling studies and submission of their Investigator's Brochure (“IB”) for Ethics Committee review to begin Phase 1 clinical trials for the first in-human treatment of concussion.
2021-07-26 08:32:00 - GlobeNewsWire
Odyssey Group International, Inc. Provides Notice of Annual Meeting of Stockholders
IRVINE, CA, July 26, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTCQB: ODYY) ("ODYY" or "the Company"), Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, today announced it plans to hold the Annual Meeting of Stockholders of Odyssey Group International, Inc. in September, 2021.
2021-06-02 07:30:00 - GlobeNewsWire
Odyssey Group International Announces Successful Completion of Their Novel Nano-Particle Drug Formulation for Treating Concussion
Irvine, CA, June 02, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTCQB: ODYY ) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, today announced the completion of their novel nano-particle drug formulation. The drug formulation was designed to enhance brain distribution of its lead drug candidate, PRV-002, to treat concussion (mild traumatic brain injury).
2021-05-26 07:29:00 - GlobeNewsWire
Odyssey Group International Announces Successful Toxicology Studies for its Concussion Drug
Enters Agreement with Contract Research Organization for Phase 1 Trial Enters Agreement with Contract Research Organization for Phase 1 Trial
2021-05-24 08:00:00 - GlobeNewsWire
Odyssey Group International, Inc. Schedules Annual Meeting of Stockholders
IRVINE, CA, May 24, 2021 (GLOBE NEWSWIRE) -- – Odyssey Group International, Inc. (OTCQB: ODYY) ("ODYY" or "the Company"), Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, today announced it plans to hold the Annual Meeting of Stockholders of Odyssey Group International, Inc. on June 30, 2021.
2021-05-13 08:05:00 - GlobeNewsWire
Odyssey Group International Welcomes Global Operations and Quality Leader Ricky Richardson to Board of Directors
IRVINE, CA, May 13, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTCQB: ODYY ) (the "Company" or "Odyssey"),a technology and asset acquisition company focused on developing unique, life-saving medical products, is pleased to welcome Ricky Richardson to the Company's Board of Directors.